The Pfizer COVID-19 vaccine of complete dose is already authorized for use in children up to 12 years in the United States, but public health officials have been working to grant similar authorizations to vaccinate younger children. A new study published today reveals that the COVID-19 “dose” vaccine of Pfizer offers young people from 5 to 11 years around 91 percent protection against symptomatic infections of SARS-COV-2.
The public has anxiously anticipated the day it is possible winter. The FDA Advisors Independent Panel will consider Pfizer data about the children’s vaccine next week.Assuming that the panel recommends the dose of the size of a child, the FDA will consider that recommendation when it finally makes its own decision on whether to expand authorization. If this authorization is granted, the CDC will be recovered, where experts will determine who is eligible to obtain the vaccine.
The authorization that is approaching, if granted, occurs in the middle of the generalized transmission of the Delta variant, which has resulted in an increase in infections among young children, some serious enough to require respiratory assistance and hospitalization. Although Delta’s cases are currently tending downward in the US. In addition, doctors reported an unusual number of CSV cases last summer before this respiratory disease appears commonly, which raises concerns about a larger number than usual this winter.